Takeda Reports Lower Profits in Latest Quarter, Closes $300M Deal with Protagonist

As a biotechnology industry analyst, I can provide you with a factual opinion about Takeda's latest quarter and their $300 million deal with Protagonist.

**Takeda Reports Lower Profits:**

Takeda Pharmaceutical (NYSE: TAK) has issued an update on its earnings guidance for FY 2023, indicating earnings per share (EPS) in the range of $3.03-$3.03 and revenue guidance of $26.9 billion-$26.9 billion. This suggests that their profits for the latest quarter might be lower compared to the previous periods. Market forecasts, such as the one on MarketBeat, indicate that the company's earnings are expected to grow by 17.65% in the coming year, from $0.34 to $0.40 per share.

**$300M Deal with Protagonist:**

Regarding the deal with Protagonist, there is currently no direct information in the provided search results. However, I can inform you that Takeda frequently engages in strategic partnerships and acquisitions to expand its portfolio in important therapeutic areas. Takeda's history of deals includes acquisitions like Adaptate Therapeutics in January 2022, which aligns with the company's strategy to invest in innovative biopharmaceuticals. If a deal with Protagonist was indeed announced, it would likely be within Takeda's goal of investing in cutting-edge technologies for their therapeutic areas.

In summary, while there is no specific information about the $300M deal with Protagonist in the provided search results, it aligns with Takeda's business strategy and their reported lower profits in the latest quarter may be a temporary hindrance to their overall growth. As an analyst, it would be prudent to closely follow official releases or announcements from Takeda to gain more detailed insights into their financial performance and strategic partnerships.